{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:07:14Z","timestamp":1784948834016,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IL-6 polymorphisms were associated to viral infection outcomes through affection of IL-6 production and it is an early indicator of tissue injury and systemic inflammatory response. The study aimed to determine whether genetic IL-6 polymorphisms, serum interleukin-6 level and inflammatory markers (Presepsin, CXCL-10, C3, and C4) are associated with the prediction of disease severity in pediatric COVID-19 patients and its possible use as a prognostic tool in pediatric patients admitted to hospital.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study was conducted on 150 children with COVID-19. Patients were divided according to the severity of infection into four groups: group I (mild) 67 cases; group II (moderate) 53 cases, group III (severe) 17 cases and group IV (critical) 14 cases. Serum Interleukin 6, CXCL-10, Presepsin, renal and liver functions, electrolytes, C3, C4, ferritin, and D dimer serum levels were assessed in all patients. The Kruskal Wallis test used to compare parametric quantitative data between studied groups and Mann Whitney test for each pair of groups. Non-parametric quantitative data was compared between studied groups using a one-way ANOVA test and post-hoc Bonferroni analysis for each pair of groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Group I: 35 males and 32 females with a median age of 16\u00a0months. Group II: 17 males and 35 females with a median age of 13\u00a0months. Group III: 6 males and 11 females with a median age of 12\u00a0months and group IV: 3 males and 11 females with a median age of 12\u00a0months. There was no statistical difference between the studied groups regarding gender and age. Serum levels of IL- 6, serum ferritin; D-dimer, Presepsin and CXCL 10 were significantly higher in both severe and critical groups than the other 2 groups (mild and moderate). ROC curve analysis showed that interleukin-6 and Presepsin were good markers for prediction of severity of COVID-19 among the diseased children. For severe cases, the sensitivity of interleukin-6 was 76.47% and specificity was 92.31%. For critical cases, the sensitivity of interleukin-6 was 71.43% and specificity was 82.35%. The sensitivity of Presepsin was 76.47% and specificity was 88.46% in severe cases. For critical cases, the sensitivity of Presepsin was 78.57% and specificity of 91.2%. There was significant difference in IL-6 572 allelic among moderate cases with the most frequent 42.3% for genotype (GC) and allelic among severe cases with the most frequent 47.1% for genotype (GC). Significant difference in IL-6 174 allelic among critical cases with the most frequent 78.6% for genotype (CC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Children whom expressed GC genotypes of IL6 (-572G\u2009&gt;\u2009C) polymorphism are at a considerably higher risk of developing a severe disease. This risk is significantly larger in the severe group of children than in children in critical condition who have GC genotypes of IL6 (-174 G\u2009&gt;\u2009C) polymorphism. While IL6 (-597G\u2009&gt;\u2009A) polymorphism has no role in COVID 19 severity in children.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-024-05071-9","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:01:37Z","timestamp":1727769697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Reem A.","family":"AbdelAziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Tamer","family":"Abd-Allah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend M.","family":"Moness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamzam Hassan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"7798","key":"5071_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265\u20139.","journal-title":"Nature"},{"issue":"7798","key":"5071_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"issue":"5","key":"5071_CR3","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.21873\/invivo.12135","volume":"34","author":"K Smetana Jr","year":"2020","unstructured":"Smetana K Jr, Rosel D, Br \u00c1bek J. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality. In Vivo. 2020;34(5):3027\u20138.","journal-title":"In Vivo"},{"key":"5071_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, et al. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"5071_CR5","doi-asserted-by":"publisher","first-page":"102695","DOI":"10.1016\/j.autrev.2020.102695","volume":"19","author":"G Halpert","year":"2020","unstructured":"Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"5071_CR6","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","volume":"19","author":"Y Jamilloux","year":"2020","unstructured":"Jamilloux Y, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"5071_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.medcli.2020.07.002","volume":"155","author":"ZS Ulhaq","year":"2020","unstructured":"Ulhaq ZS, Soraya GV. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia. Med Clin (Barc). 2020;155(12):548\u201356.","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"5071_CR8","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/j.autrev.2020.102569","volume":"19","author":"J Alijotas-Reig","year":"2020","unstructured":"Alijotas-Reig J, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;19(7):102569.","journal-title":"Autoimmun Rev"},{"key":"5071_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ijid.2020.04.061","volume":"95","author":"TP Velavan","year":"2020","unstructured":"Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304\u20137.","journal-title":"Int J Infect Dis"},{"key":"5071_CR10","unstructured":"Tobias H, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv. 2020:2020.04.01.20047381."},{"key":"5071_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ijid.2020.05.055","volume":"96","author":"F Zeng","year":"2020","unstructured":"Zeng F, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467\u201374.","journal-title":"Int J Infect Dis"},{"key":"5071_CR12","doi-asserted-by":"publisher","first-page":"607647","DOI":"10.3389\/fped.2020.607647","volume":"8","author":"M Samprathi","year":"2020","unstructured":"Samprathi M, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2020;8:607647.","journal-title":"Front Pediatr"},{"key":"5071_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","volume":"10","author":"L Velazquez-Salinas","year":"2019","unstructured":"Velazquez-Salinas L, et al. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019;10:1057.","journal-title":"Front Microbiol"},{"issue":"6","key":"5071_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.gene.6363881","volume":"3","author":"N Haukim","year":"2002","unstructured":"Haukim N, et al. Cytokine gene polymorphism in human disease: on-line databases, Supplement 2. Genes Immun. 2002;3(6):313\u201330.","journal-title":"Genes Immun"},{"issue":"10","key":"5071_CR15","first-page":"17036","volume":"8","author":"L Chang","year":"2015","unstructured":"Chang L, et al. The association between three IL-6 polymorphisms and HBV-related liver diseases: a meta-analysis. Int J Clin Exp Med. 2015;8(10):17036\u201345.","journal-title":"Int J Clin Exp Med"},{"key":"5071_CR16","doi-asserted-by":"crossref","unstructured":"Vitkauskaite A, et al. IL-6 597A\/G (rs1800797) and 174G\/C (rs1800795) Gene Polymorphisms in the Development of Cervical Cancer in Lithuanian Women. Medicina (Kaunas). 2021;57(10).","DOI":"10.3390\/medicina57101025"},{"key":"5071_CR17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/jmv.27477","volume":"94","author":"M Heidari Nia","year":"2022","unstructured":"Heidari Nia M, Rokni M, Mirinejad S, Kargar M, Rahdar S, Sargazi S, Sarhadi M, Saravani R. Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: a case-control study and in silico analyses. J Med Virol. 2022;94:1502\u201312.","journal-title":"J Med Virol"},{"key":"5071_CR18","doi-asserted-by":"publisher","first-page":"e24400","DOI":"10.1002\/jcla.24400","volume":"36","author":"HN Ali","year":"2022","unstructured":"Ali HN, Niranji SS, Al-Jaf SMA. Association of tumor necrosis factor alpha\u2013 308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi kurdish population. J Clin Lab Anal. 2022;36:e24400.","journal-title":"J Clin Lab Anal"},{"issue":"12","key":"5071_CR19","doi-asserted-by":"publisher","first-page":"e0591","DOI":"10.1097\/CCE.0000000000000591","volume":"3","author":"FL Mabrey","year":"2021","unstructured":"Mabrey FL, et al. Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019. Crit Care Explor. 2021;3(12):e0591.","journal-title":"Crit Care Explor"},{"issue":"1","key":"5071_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.52547\/iem.9.1.35","volume":"9","author":"FH AL-Khikani","year":"2023","unstructured":"AL-Khikani FH, Abdulridha Alkhafaji Z. Impact of IL-35 and presepsin on immunological, hematological, and biochemical parameters in COVID-19 patients. J Infect Epidemiol Microbiol. 2023;9(1):35\u201342.","journal-title":"J Infect Epidemiol Microbiol"},{"issue":"Suppl 2","key":"5071_CR21","first-page":"S286","volume":"15","author":"AD Al-Hussainy","year":"2022","unstructured":"Al-Hussainy AD, AL-Khikani FH, Hussein AZ, Alshamary RS. Correlation between severe acute respiratory syndrome Coronavirus-2 and cytomegalovirus. Medical Journal of Dr DY Patil University. 2022;15(Suppl 2):S286\u201390.","journal-title":"Medical Journal of Dr. DY Patil University"},{"issue":"1","key":"5071_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s10020-021-00390-4","volume":"27","author":"NI Lor\u00e8","year":"2021","unstructured":"Lor\u00e8 NI, et al. CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Mol Med. 2021;27(1):129.","journal-title":"Mol Med"},{"issue":"7","key":"5071_CR23","doi-asserted-by":"publisher","first-page":"e0254367","DOI":"10.1371\/journal.pone.0254367","volume":"16","author":"R Ravindran","year":"2021","unstructured":"Ravindran R, et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PLoS ONE. 2021;16(7):e0254367.","journal-title":"PLoS ONE"},{"key":"5071_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","volume":"32","author":"VM Holers","year":"2014","unstructured":"Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433\u201359.","journal-title":"Annu Rev Immunol"},{"key":"5071_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, et al. Complement System Part II: Role in Immunity. Front Immunol. 2015;6:257.","journal-title":"Front Immunol"},{"issue":"4","key":"5071_CR26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, et al. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020;181(4):914\u2013921.e10.","journal-title":"Cell"},{"issue":"2","key":"5071_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00431-020-03747-9","volume":"180","author":"S Torretta","year":"2021","unstructured":"Torretta S, et al. Incidental lowering of otitis-media complaints in otitis-prone children during COVID-19 pandemic: not all evil comes to hurt. Eur J Pediatr. 2021;180(2):649\u201352.","journal-title":"Eur J Pediatr"},{"key":"5071_CR28","doi-asserted-by":"crossref","unstructured":"World Health Organization.\u00a0(2020).\u00a0Clinical management of COVID-19: interim guidance, 27 May 2020.\u00a0World Health Organization. https:\/\/iris.who.int\/handle\/10665\/332196.","DOI":"10.15557\/PiMR.2020.0004"},{"key":"5071_CR29","doi-asserted-by":"publisher","first-page":"155889","DOI":"10.1016\/j.cyto.2022.155889","volume":"154","author":"S Falahi","year":"2022","unstructured":"Falahi S, et al. Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population. Cytokine. 2022;154:155889.","journal-title":"Cytokine"},{"key":"5071_CR30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/cid\/ciaa449.[PubMed][CrossRef][GoogleScholar]","volume":"71","author":"X Chen","year":"2020","unstructured":"Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J, Li F. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) Is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2020;71:1937\u201342. https:\/\/doi.org\/10.1093\/cid\/ciaa449.[PubMed][CrossRef][GoogleScholar].","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5071_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1\u20139.","journal-title":"Rev Med Virol"},{"key":"5071_CR32","doi-asserted-by":"publisher","first-page":"108929","DOI":"10.1016\/j.clim.2022.108929","volume":"235","author":"MM Alseoudy","year":"2022","unstructured":"Alseoudy MM, et al. Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study. Clin Immunol. 2022;235:108929.","journal-title":"Clin Immunol"},{"key":"5071_CR33","doi-asserted-by":"publisher","first-page":"111980","DOI":"10.1016\/j.biopha.2021.111980","volume":"142","author":"F Maione","year":"2021","unstructured":"Maione F, et al. Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomed Pharmacother. 2021;142:111980.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"5071_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7883\/yoken.JJID.2021.046","volume":"74","author":"F Kerget","year":"2021","unstructured":"Kerget F, Kerget B. Frequency of Interleukin-6 rs1800795 (-174G\/C) and rs1800797 (-597G\/A) Polymorphisms in COVID-19 Patients in Turkey Who Develop Macrophage Activation Syndrome. Jpn J Infect Dis. 2021;74(6):543\u20138.","journal-title":"Jpn J Infect Dis"},{"issue":"10","key":"5071_CR35","doi-asserted-by":"publisher","first-page":"e0293639","DOI":"10.1371\/journal.pone.0293639","volume":"18","author":"IJ Ganda","year":"2023","unstructured":"Ganda IJ, Putri TK, Rauf S, Laompo A, Pelupessy NM, Lawang SA, et al. IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection\u2019s mortality in children. PLOS ONE. 2023;18(10):e0293639.","journal-title":"PLOS ONE"},{"issue":"2","key":"5071_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01.MXE.0000415225.85003.47","volume":"1","author":"S Ismail","year":"2012","unstructured":"Ismail S, Essawi M. Genetic polymorphism studies in humans. Middle East J Med Genet. 2012;1(2):57\u201363.","journal-title":"Middle East J Med Genet"},{"key":"5071_CR37","doi-asserted-by":"crossref","unstructured":"Shalaby HM, et al. Assessment of interleukin-6 role in detecting coronavirus disease 2019 severity, mortality, and its control: A cohort study. 2023;72(2):183\u2013190.","DOI":"10.4103\/ecdt.ecdt_75_22"},{"issue":"1","key":"5071_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12967-020-02571-x","volume":"18","author":"J Zhang","year":"2020","unstructured":"Zhang J, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med. 2020;18(1):406.","journal-title":"J Transl Med"},{"issue":"1","key":"5071_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/iji.12605","volume":"50","author":"S Verma","year":"2023","unstructured":"Verma S, Verma S, Khan FH, Siddiqi Z, Raza ST, Abbas M, Mahdi F. Genetic polymorphisms of IL6 gene -174G > C and -597G > A are associated with the risk of COVID-19 severity. Int J Immunogenet. 2023;50(1):5\u201311.","journal-title":"Int J Immunogenet"},{"key":"5071_CR40","doi-asserted-by":"publisher","unstructured":"Bharadwaj, N.K.a.S., Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans. 2020.\u00a0https:\/\/doi.org\/10.1080\/07391102.2020.1776640.","DOI":"10.1080\/07391102.2020.1776640"},{"key":"5071_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijid.2022.02.054","volume":"118","author":"HH Assal","year":"2022","unstructured":"Assal HH, et al. Presepsin as a Novel Biomarker in predicting In-hospital Mortality in Patients With COVID-19 Pneumonia. Int J Infect Dis. 2022;118:155\u201363.","journal-title":"Int J Infect Dis"},{"key":"5071_CR42","doi-asserted-by":"publisher","first-page":"654587","DOI":"10.3389\/fimmu.2021.654587","volume":"12","author":"F Caldarale","year":"2021","unstructured":"Caldarale F, et al. Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-\u03b3 Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. Front Immunol. 2021;12:654587.","journal-title":"Front Immunol"},{"issue":"1","key":"5071_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jmv.26164","volume":"93","author":"A Fukada","year":"2021","unstructured":"Fukada A, Kitagawa Y, Matsuoka M, et al. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J Med Virol. 2021;93(1):99\u2013101. https:\/\/doi.org\/10.1002\/jmv.26164. PMID: 32530491; PMCID: PMC7307131.","journal-title":"J Med Virol"},{"key":"5071_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2020.04.020","volume":"507","author":"M Zaninotto","year":"2020","unstructured":"Zaninotto M, et al. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161\u20133.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"5071_CR45","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.21608\/nrmj.2021.190249","volume":"5","author":"S M Farag","year":"2021","unstructured":"M Farag S, et al. Presepsin as a predictive indicator of severity in Coronavirus disease-2019 (COVID-19). Novel Res Microbiol J. 2021;5(4):1325\u201337.","journal-title":"Novel Res Microbiol J"},{"key":"5071_CR46","doi-asserted-by":"crossref","unstructured":"\u00c7a\u011flar FNT, et al. Serum Presepsin Levels among Patients with COVID-19. 2022;13(1):17\u201322.","DOI":"10.4103\/injms.injms_77_21"},{"key":"5071_CR47","doi-asserted-by":"crossref","unstructured":"Zinellu A, Mangoni AA. Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. 2021;12.","DOI":"10.3389\/fimmu.2021.696085"},{"key":"5071_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119245","volume":"272","author":"LE Santiesteban-Lores","year":"2021","unstructured":"Santiesteban-Lores LE, et al. A double edged-sword - The Complement System during SARS-CoV-2 infection. Life Sci. 2021;272: 119245.","journal-title":"Life Sci"},{"issue":"6","key":"5071_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41577-020-0320-7","volume":"20","author":"AM Risitano","year":"2020","unstructured":"Risitano AM, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343\u20134.","journal-title":"Nat Rev Immunol"},{"key":"5071_CR50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2147\/IJGM.S348519","volume":"15","author":"H Jiang","year":"2022","unstructured":"Jiang H, et al. Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. Int J Gen Med. 2022;15:849\u201357.","journal-title":"Int J Gen Med"},{"issue":"1","key":"5071_CR51","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41598-021-81300-w","volume":"11","author":"X He","year":"2021","unstructured":"He X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830.","journal-title":"Sci Rep"},{"issue":"7","key":"5071_CR52","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/jth.14850","volume":"18","author":"M Panigada","year":"2020","unstructured":"Panigada M, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738\u201342.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"5071_CR53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.medcli.2020.11.030","volume":"156","author":"F Deng","year":"2021","unstructured":"Deng F, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021;156(7):324\u201331.","journal-title":"Med Clin (Barc)"},{"issue":"7","key":"5071_CR54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2014.302","volume":"312","author":"LB VanWagner","year":"2014","unstructured":"VanWagner LB, Green RM. Elevated serum ferritin. JAMA. 2014;312(7):743\u20134.","journal-title":"JAMA"},{"issue":"20","key":"5071_CR55","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1001\/jama.2020.6266","volume":"323","author":"D Kim","year":"2020","unstructured":"Kim D, et al. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA. 2020;323(20):2085\u20136.","journal-title":"JAMA"},{"issue":"1","key":"5071_CR56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1148\/radiol.2020200230","volume":"295","author":"M Chung","year":"2020","unstructured":"Chung M, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202\u20137.","journal-title":"Radiology"},{"issue":"11","key":"5071_CR57","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jama.2021.2091","volume":"325","author":"LR Feldstein","year":"2021","unstructured":"Feldstein LR, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325(11):1074\u201387.","journal-title":"JAMA"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-05071-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:05:47Z","timestamp":1727773547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-05071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5071"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-05071-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research Ethics Committee, Faculty of Medicine, Minia University, Egypt, and approval was done according to The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans. The approval number is 35: 2021. Informed written consents were obtained from all patients\u2019 parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"625"}}